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Abstract. Thymidylate synthase, as a rate-limiting step in
DNA synthesis, catalyses the conversion of dUMP into dTMP
using 5,10-methylenotetrahydrofolate as the methyl donor.
Two polymorphisms have been described in this gene: a repeat
polymorphism in the 5' promoter enhancer region (3R versus
2R) and a 6 bp deletion in the 3' unstranslated region. Both of
these may affect protein levels. The present case control study
was aimed at investigating the influence of these two poly-
morphisms on the development of colorectal cancer (CRC), as
well as their potential interaction with folate, vitamin B6 and
vitamin B12 intake. A total of 196 cases and 200 controls,
matched for age and sex distribution, were included in the
study. No association was found between CRC and the 28 bp
repeat polymorphism, but it was observed that individuals with
the 6 bp/del and del/del genotypes had a significantly lower
risk of developing the disease (OR=0.47; 95% CI 0.30-0.72).
A combined genotype (2R/2R; 6 bp/del+del/del) was also
found, which was associated with an even lower risk of
developing of the disease (OR=0.42; 95% CI 0.26-0.69). No
significant interaction between these polymorphisms and
vitamin intake was observed. These results indicate for the
first time that the 6 bp/del allele might be a protective factor
in the development of CRC, independent of the intake of
methyl group donors.
Introduction
Colorectal cancer (CRC) is today one of the most prevalent
cancers in developed societies (1), representing 9.4% of cancers
in males and 10.1% in females (2). In Portugal, it is among
the leading causes of cancer, and has one of the highest
mortality rates in Europe (3,4). 
It is well known that the etiology of this tumour is multi-
factorial, involving both environmental and genetic factors
(5,6). One of the factors that has been associated with a
decreased risk of CRC is the high consumption of folate (7-9).
Several studies suggest an inverse association between folate
status, either its intake or blood measurements, and the risk
of this malignancy (10). The potential mechanisms whereby
deficiency enhances and supplementation suppresses CRC
have been extensively reviewed (11-13), and are related to the
involvement of this vitamin in the mediation of the transfer of
1-carbon units (Fig. 1). Through this apparently simple func-
tion, folate plays a key role in a number of processes related to
DNA integrity, such as DNA synthesis and DNA methylation
(11-15). This explains why a number of in vitro and in vivo
studies have shown that folate deficiency results in DNA
strand breaks, DNA hypomethylation, impaired DNA repair
and increased mutagenesis (11-15).
In a number of these studies, the observed inverse associ-
ation between folate status and CRC risk was further modified
by genetic polymorphisms of the enzymes involved in folate
metabolism, namely methylene tetrahydrofolate reductase
(MTHFR) and thymidylate synthase (TS). The former is an
enzyme critical to folate metabolism that catalyses the irre-
versible conversion of 5,10-methyleneTHF into 5-methylTHF,
thereby playing an important role in DNA methylation and
synthesis (Fig. 1). A number of previous studies suggest that
folate supplementation might be particularly effective in
reducing the risk of CRC in subjects carrying the polymorphic
allele C677T for MTHFR (16-19), as this polymorphism
causes thermolability and reduced MTHFR activity. TS is the
enzyme responsible for the conversion of deoxyuridine mono-
phosphate (dUMP) into deoxythymidine monophosphate
(dTMP), and competes with MTHFR for 5,10-methyleneTHF
as the substrate of this methylation reaction (20). In respect
to TS, a tandem repeat polymorphism has been identified in
the 5'UTR enhancer region of the TS promoter that contains
either triple (3R) or double (2R) repeats of a 28-bp sequence
(21). Individuals homozygous for triple repeats have TS
mRNA levels 3.6 times higher than those homozygous for
the double repeat genotype (22). Another 6-bp deletion in the
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3'UTR of the TS gene has been identified, and previous studies
have reported that tumour mRNA levels in patients with a
homozygous wild-type genotype are 4.2-fold higher than those
of patients with a homozygous variant genotype (23). Most
studies have examined the importance of these polymorphisms
in predicting either survival or response to 5-FU-based chemo-
therapy in tumours with a high expression of TS that are
responding poorly to this agent and have a worse survival prog-
nosis (24). To our knowledge, very few studies have examined
whether these polymorphisms of the TS gene influence the
risk of developing colorectal neoplasms. The results obtained
from those that have been conducted are subject to some
discrepancies (25-31).
The aim of this case-control study was to examine the
potential influence of the two abovementioned TS UTR
(untranslated region) polymorphisms on the development of
CRC in a Portuguese population group, as well as to investigate
potential interactions between these polymorphisms and the
intake of methyl donor compounds, such as folate and vitamins
B6 and B12.
Materials and methods
Study population. This case-control study was performed at the
Instituto Português de Oncologia de Lisboa Francisco Gentil
EPE (IPOLFG). The study was approved by the Scientific and
Ethics committees of IPOLFG, and both patients and controls
gave their informed written consent for participation.
The patient group comprised 196 subjects (104 males,
92 females; mean age 64.2±11.3) with a histologic diagnosis of
CRC, and the control group 200 healthy blood donor volun-
teers recruited from the same institute with a similar sex and
age distribution (106 males, 94 females; mean age 62.2±12.1)
and with no previous history of cancer at any site. Of the
patients, 169/196 (86.5%) had recently been diagnosed with
CRC, while the remaining 27 (13.5%) were being treated for
disease relapse. In terms of previous therapies, 119/196
(60.7%) had not received any form of treatment, 28/196
(14.3%) had already been operated on, 13/196 (6.6%) had
undergone pelvic radiotherapy, 11/196 (5.6%) had received
one or more cycles of chemotherapy, and the remaining 25/196
(12.8%) had undergone combined forms of treatment. TNM
staging was as follows: stage I, 24/178 (13.5%); stage II,
64/178 (35.9%); stage III, 53/178 (29.8%); stage IV, 37/178
(20.8%). All subjects were Caucasian.
Nutritional evaluation. In order to quantify folate, vitamin B6
and vitamin B12 intake, we used a Food Frequency Question-
naire validated for a Portuguese population (32). Participants
were asked to recall their habits in the year before CRC diag-
nosis (patients), or in the year prior to the interview (controls).
Data on the type and quantity of food intake was then analysed
using modified database Food Processor software, version 7
(Esha Research Inc. Salem, USA), which includes some
Portuguese food items, allowing for the quantification of differ-
ent macro- and micronutrients. Nutrient values were calculated
from food and from supplements (taken by 11/196 of patients
and by none of the controls).
Genotyping of polymorphisms. DNA was extracted from
peripheral blood collected by digital puncture using the
Generation Capture Card Kit (Gentra Systems). Fragments
were amplified using specific primers for each allelic determi-
nation (5'-CCTGGCGCACGCTCTCTA-3' and 5'-GATCTG
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Figure 1. Folic acid cycle.
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CCCCAGGTACTGC-3' for the 28 bp polymorphism; 5'-TTT
CACAAGCTATTCCCTCAAA-3' and 5'-CAGAATGAA
CAAAGCGTGGA-3' for the 6 bp polymorphism). Both
polymorphism fragments were amplified using 1.5 U of Taq
polymerase (Fermentas, Ontario, Canada) with a primer
concentration of 200 nM and a Mg2+ concentration of 2.5 mM.
The 28 bp polymorphism fragment was amplified in the pres-
ence of 2X concentrated Enhancer Solution (Invitrogen, CA,
USA). Amplification steps were as follows: 95˚C for 10 min,
followed by 40 cycles at 95˚C for 1 min, 60˚C for 1 min and
72˚C for 1 min. A final extension step was performed at 72˚C
for 10 min.
The 28 bp TS genotype was determined by separation of
the fragments on 2% agarose gel. In the case of the 6 bp dele-
tion genotype, Restriction Fragment Length Polymorphism
(RFLP) analysis was used with 10 U of DraI restriction
enzyme (New England Biolabs, MA, USA) incubated at
37˚C for 2 h, followed by separation of the fragments on 4%
agarose gel.
Statistical analysis. Odds ratio (OR) analysis was performed
using binary logistic regression adjusted for sex, age and
family history. Interaction between the polymorphisms and
nutrient intake was evaluated by the likelihood ratio test. All
analyses were performed using SPSS software, version 15.0.
Results
Of the total 196 patients and 200 controls included in this study,
173 patients and 170 controls were used in the analysis of the
28 bp repeat polymorphism, and 185 cases and 193 controls
were used in the 6 bp deletion polymorphism. This was because
certain DNA samples had failed to be amplified by PCR.
The mean daily intake of folate and vitamins B6 and B12
of the patients and controls is shown in Table I. To test
whether the intake of these nutrients influenced the risk of
developing CRC, patients and controls were respectively
divided into two groups according to whether their intake
was higher or lower than the calculated median of the control
population, followed by an OR calculation (Table I). A daily
intake of folate above 422.2±161.3 μg/day was found to be
associated with a 33% decreased risk of developing CRC
(OR=0.67; 95% CI 0.45-1.02). No significant differences were
observed for vitamin B6 or B12.
Genotypic and allelic distributions of the 28 bp repeat
polymorphism and the 6 bp deletion polymorphism for both
cases and controls are presented in Table II. In the 28 bp
repeat polymorphism, one sole individual was found to have
four repeats. Since the functional consequences of this four
repeat allele are not well known, the subject was excluded
from the analysis. Regarding genotypic distribution, both
cases and controls were in Hardy-Weinberg equilibrium for
the two polymorphisms. No significant differences between
cases and controls were observed in respect to the 28 bp
repeat polymorphism (P>0.05). In contrast, the 6 bp deletion
polymorphism was found to have a statistically significant
(P<0.010) higher frequency of the del allele in controls as
compared to cases. This finding strengthens the hypothesis
that the presence of the del allele, in either heterozygosity or
homozygosity, represents a protective effect. As shown in
Table III, the 6 bp/del and del/del genotypes were observed to
be associated with a reduction in the risk of CRC (OR=0.47;
95% CI 0.30-0.72). However, the 28 bp repeat polymorphism
showed no significant association with the risk of CRC
(OR=1.33; 95% CI 0.74-2.39).
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Table I. Mean intake of nutrients in the two population groups and odds ratio of the interaction between nutrient intake and
colorectal cancer susceptibility.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Mean intake (μg/day) Odds ratio (95% CI)
––––––––––––––––––––––––––––––––– –––––––––––––––––––––––––––––––––––––––––
Nutrients Cases Controls Low High P-value
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Vitamin B6 2.83±1.06 2.85±0.98 1 0.71 (0.52-1.07) 0.10
Vitamin B12 14.53±9.05 14.36±8.22 1 0.89 (0.59-1.34) 0.58
Folic acid 401.57±161.88 433.40±161.32 1 0.67 (0.45-1.02) 0.06
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Nutrient intake was divided in two groups: low, meaning intake lower than the calculated median, and high, meaning intake higher than the
median. Control median intake of: vitamin B6, 2.82 μg/day; vitamin B12, 12.63 μg/day; folic acid, 422.22 μg/day.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Table II. Allelic and genotypic distribution of the 28 bp
tandem repeat and 6 bp deletion polymorphism alleles in the
two population groups.
––––––––––––––––––––––––––––––––––––––––––––––––– 
No. cases (%) No. controls (%) P-value
––––––––––––––––––––––––––––––––––––––––––––––––– 
28 bp repeat
2R/2R 24   (13.9) 30   (17.6) 0.330
2R/3R 102   (59.0) 87   (51.2)
3R/3R 47   (27.1) 53   (31.2)
2R 150 (0.434) 147 (0.432) 1.000
3R 196 (0.566) 193 (0.568)
6 bp deletion
6 bp/6 bp 99   (53.5) 72   (37.3) 0.006
6 bp/del 69   (37.3) 100   (51.8)
del/del 17     (9.2) 21   (10.9)
6 bp 267 (0.722) 244 (0.632) <0.010
del 103 (0.278) 142 (0.368)
––––––––––––––––––––––––––––––––––––––––––––––––– 
Analysis performed using the χ2 test.
––––––––––––––––––––––––––––––––––––––––––––––––– 
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OR analysis was performed in order to test whether there
could be a combined genotype of this gene influencing CRC
development. The analysis compared individuals homozygous
for the 2R allele in the 28 bp repeat polymorphism and those
heterozygous or homozygous for the del allele in the 6 bp
deletion polymorphism (2R/2R, 6 bp/del+6 bp/del) with the
remaining individuals. It was observed that individuals carrying
this combined genotype were at an even lower risk of develop-
ing CRC (OR=0.42; 95% CI 0.29-0.73).
When the interaction between these polymorphisms and
the intake of the three vitamins was tested, no significant
associations were observed for either of the polymorphisms
(data not shown). We also found no correlation between the
polymorphisms and tumour location, disease staging, response
to chemoradiotherapy or survival (data not shown).
Discussion
Folate, a water soluble B vitamin, has been shown to protect
against cancer at several sites, including the colon (11,13).
Epidemiologic and clinical studies indicate that dietary folate
intake and blood folate levels are inversely associated with
the risk of developing both adenomas and CRC (7-9). Animal
studies have also unequivocally established a causal relation-
ship between folate deficiency and CRC (33). In a subsequent
study (34), Kim et al demonstrated that the modulating effect
of folate on CRC was dependent on both the timing and dose
of folate intervention. More recently, some authors have raised
the question of whether folate supplements taken by indi-
viduals already harbouring pre-malignant lesions can in fact
increase the risk of CRC (35,36). The mechanisms by which
folate intake modulates the risk of malignancy are probably
related to the fact that folate supplies the methyl group for
either DNA methylation or for uracil conversion to thymidine
(10,12,37). Recent epidemiologic molecular studies have also
suggested that the protective effect of folate could be further
modified by interactions with genetic polymorphisms in the
genes codifying the enzymes involved in folate metabolism.
The most extensively studied genetic polymorphism is the
C677T polymorphism of the MTHFR gene, which may influ-
ence the risk of CRC according to folate status, alcohol intake
and the supply of methyl group donors, such as methionine,
vitamins B6 and B12 (13,38).
Most studies on TS, which converts dUMP to dTMP as a
rate-limiting step in DNA synthesis, have examined the impact
of the 28 bp repeat and 6 bp/del polymorphisms on prognosis,
or have evaluated them as indicators of response to 5-FU.
Few studies have evaluated the influence of these polymor-
phisms on the aetiology of CRC, and those that have done
have achieved discrepant results. For example, in respect to
colorectal adenomas, which are the precursor lesions for CRC,
Ulrich et al (23) observed that the TS 28 bp tandem repeat
polymorphism was not an independent risk factor for colorectal
adenomas. However, there was a statistically significant gene-
nutrient interaction with dietary folate intake: in individuals
with the 3R/3R genotype, folate intake over 440 μg/day was
associated with decreased risk, whereas in individuals with
the 2R/2R variant, a 1.5-fold increased risk was observed with
high folate intake. In the same study, the TS 6 bp deletion
polymorphism was not demonstrated to modify the risk for
colorectal adenomas, nor was any association with folate
intake found. In contrast, in a case-control study nested within
a prospective Health Professionals Follow-up Study, Chen
et al (39) observed significant interaction between the TS
28 bp promoter polymorphism and alcohol intake, which
modulated the risk of developing colorectal adenomas. The
effect of the 6 bp/del polymorphism was not examined in that
study (39).
As regards the influence of these polymorphisms on CRC
development Ulrich et al observed that men carrying the
2R/2R genotype had a 30% decreased risk of CRC compared
to those with the homozygous 3R genotype. No association
was found for the 6 bp polymorphism (31). Chen et al (40),
using the same study design within the prospective Physicians'
Health Study, observed no association between the risk of
CRC and the 6 bp/del polymorphism, However, in regard to
the 28 bp polymorphism, individuals with the 2R allele had a
non-significant decreased risk of CRC compared to those with
the 3R/3R genotype. This suggests a protective effect for the
2R allele. Additionally, none of the compound genotypes sig-
nificantly influenced the risk of CRC, nor was any modulating
effect of folate status observed. These results are in only partial
agreement with the current findings. This study also demon-
strated that folate intake per se had a protective effect against
the risk of developing CRC (OR=0.67; 95% CI 0.45-0.99).
Our findings with respect to TS polymorphisms were similar
to those of Chen et al (40) and Ulrich et al (31), in that differ-
ences regarding the 28 bp polymorphism were non-significant.
However, in contrast with the results obtained by Ulrich et al
(31), who found that the TS 6 bp polymorphic allele was not
associated with a decreased risk of CRC, in the present study
individuals homozygous or heterozygous for this variant car-
ried a significantly and unequivocally lower risk of developing
CRC. Furthermore, by combining the protective effects of
the 6 bp/del allele and the 28 bp 2R allele, we found a com-
bined genotype of the TS gene (2R/2R, 6 bpdel/del+6 bpdel),
which was associated with a 58% decreased risk of developing
CRC. In agreement with Chen et al (40), no significant inter-
actions between these genetic polymorphisms and folate intake
were observed in the present study.
The reasons for the discrepancies observed among these
studies are not readily apparent. However, it is worth noting
that all previous studies on the influence of these genetic poly-
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Table III. Odds ratio analysis for the polymorphisms.
––––––––––––––––––––––––––––––––––––––––––––––––– 
Odds ratio (95% CI)
––––––––––––––––––––––––––––––––––
Polymorphism 2R/2R 2R/3R+3R/3R P-value
––––––––––––––––––––––––––––––––––––––––––––––––– 
28 bp repeat 1 1.29 (0.71-2.36) 0.41
––––––––––––––––––––––––––––––––––––––––––––––––– 
6 bp/6 bp 6 bp/del+del/del
––––––––––––––––––––––––––––––––––––––––––––––––– 
6 bp deletion 1 0.47 (0.30-0.72) 0.001
–––––––––––––––––––––––––––––––––––––––––––––––––
Odds ratios were calculated using binary logistic regression adjusted
for age, sex and family history.
–––––––––––––––––––––––––––––––––––––––––––––––––
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morphisms on the risk of developing colorectal adenomas or
CRC were performed in North America, where the diet is
certainly very different from the average dietary intake in
Portugal. One could also speculate that interactions with other
genetic polymorphisms could explain these differing results.
However, no statistically significant differences were found
between the genotypic distribution of the present study and
that of others (31,40), with the exception of the genotypic
distribution of the 28 bp repeat allele compared to the cancer
population used by Ulrich et al (P<0.05) (data not shown) (31).
In a previous study using the same population as the current
study, we analysed polymorphisms in folate metabolizing
enzymes involved in the DNA methylation cycle, including
C677T polymorphisms of methylene terahydrofolate reductase
(MTHFR). No interaction was observed between the two poly-
morphisms of TS analysed in the present study and the C677T
polymorphism of MTHFR in terms of modulating the risk of
CRC (unpublished results).
Altogether, the findings of this and previous studies (31,40)
suggest that alleles resulting in decreased gene expression
exhibit a protective effect against the development of CRC.
As these polymorphisms contribute to the final intracellular
concentration of TS protein, we further investigated the role
of two combined genotypes (2R/2R+6 bp/del, del/del) in
the development of CRC. Since the 2R allele is associated
with a decreased translation level of the TS mRNA, and the
del allele with TS mRNA instability, individuals with these
combined genotypes should have a decreased TS protein
level. Indeed, such individuals were found to have a 2.4x
reduction in the risk of developing CRC. It is therefore safe
to hypothesize that low TS protein levels lead to a reduction
in the risk of developing CRC. This may be due to the fact
that TS and MTHFR compete for the same substrate (5,10-
methyleneTHF). High TS levels would lead to a depletion of
the 5,10-methyleneTHF pool, which could impair the conver-
sion of homocysteine into methionine (Fig. 1). Methionine
is the immediate precursor of S-Adenosylmethionine, the
universal methyl donor for several compounds, including
DNA. Thus, at least theoretically, elevated TS activity could
impair DNA methylation, which has been widely recognized
as an important epigenetic mechanism for the control of gene
transcription. This hypothesis needs to be further confirmed,
and is currently being tested.
To the best of our knowledge, this is the first study
performed in a southern European country demonstrating a
protective effect for both the 6 bp/del allele per se, as well as
for a compound genotype including this allele and the 2R
allele from the 28 bp polymorphism. These protective effects
do not appear to be mediated by folate or by other methyl
group donor intake.
Although future studies are required to elucidate why the
same polymorphisms have differing roles in different popula-
tions, our results contribute to the understanding of the
complex interaction between genes and nutrients in the
modulation of cancer risk.
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